Medtronic PLC (NYSE:MDT – Get Free Report) gapped up before the market opened on Tuesday following a better than expected earnings announcement. The stock had previously closed at $90.65, but opened at $94.00. Medtronic shares last traded at $91.97, with a volume of 3,671,154 shares traded.
The medical technology company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.39 by $0.06. The firm had revenue of $9.76 billion for the quarter, compared to the consensus estimate of $9.55 billion. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The business’s quarterly revenue was up 13.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS.
Medtronic Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be given a $0.72 dividend. The ex-dividend date is Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.1%. Medtronic’s payout ratio is 77.21%.
Medtronic News Roundup
- Positive Sentiment: Medtronic raised its fiscal 2027 guidance, increasing organic revenue growth expectations to 7.25%–7.75% and diluted non-GAAP EPS guidance to $5.94–$6.00. The company cited broad-based demand and strength in newer growth platforms. Medtronic boosts fiscal 2027 forecasts on heart device demand
- Positive Sentiment: Fiscal first-quarter revenue rose 13.7% to $9.756 billion, exceeding the $9.55 billion analyst consensus. Adjusted EPS was $1.45 versus expectations of $1.39, while GAAP net income was $1.47 billion and GAAP EPS was $1.14. Medtronic Q1 Revenue Rises 13.7% to $9.756 Billion, Raises FY27 Guidance
- Positive Sentiment: All major businesses posted strong growth: Cardiovascular revenue increased 19.5%, Neuroscience 10.3%, Medical Surgical 10.0%, and Diabetes 16.9% on a reported basis. Cardiovascular demand was especially strong in complex procedures. Medtronic Lifts Outlook, Invests Over $700 Million in Heart Tech and Robotics
- Positive Sentiment: Medtronic is investing more than $700 million in heart technology and robotics, including a strategic investment in Pi-Cardia to advance complex transcatheter aortic valve replacement procedures. The spending could strengthen longer-term growth but may increase near-term investment costs. Medtronic Announces Strategic Investment in Pi-Cardia
- Neutral Sentiment: An additional fiscal week contributed approximately $570 million to first-quarter organic revenue, creating a comparison benefit investors will need to consider when assessing the underlying growth rate.
- Negative Sentiment: Recent insider activity was entirely selling, with three reported open-market sales and no purchases over the past six months. Institutional positioning was also mixed, with major investors both adding to and reducing their holdings.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently weighed in on MDT shares. BTIG Research reiterated a “buy” rating and set a $91.00 price objective on shares of Medtronic in a research report on Tuesday, August 18th. Royal Bank Of Canada restated an “outperform” rating and issued a $118.00 target price on shares of Medtronic in a report on Thursday, June 4th. Rothschild & Co Redburn decreased their price target on Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a report on Friday, June 5th. Wells Fargo & Company dropped their price objective on Medtronic from $114.00 to $102.00 and set an “overweight” rating on the stock in a research note on Thursday, June 4th. Finally, Robert W. Baird cut their target price on Medtronic from $93.00 to $85.00 and set a “neutral” rating on the stock in a research report on Thursday, June 4th. Eighteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Medtronic has an average rating of “Moderate Buy” and a consensus target price of $99.79.
View Our Latest Research Report on MDT
Insider Activity at Medtronic
In related news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the transaction, the executive vice president directly owned 37,227 shares in the company, valued at $2,994,539.88. This trade represents a 10.11% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.27% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of MDT. Anfield Capital Management LLC raised its holdings in shares of Medtronic by 410.7% in the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 230 shares during the last quarter. Monetary Solutions Ltd purchased a new stake in shares of Medtronic in the fourth quarter valued at about $27,000. Acumen Wealth Advisors LLC bought a new position in shares of Medtronic during the fourth quarter valued at about $29,000. IAG Wealth Partners LLC bought a new position in shares of Medtronic during the second quarter valued at about $30,000. Finally, Imprint Wealth LLC purchased a new position in Medtronic during the third quarter worth about $31,000. Institutional investors and hedge funds own 82.06% of the company’s stock.
Medtronic Stock Performance
The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13. The stock has a market cap of $117.07 billion, a PE ratio of 24.57, a price-to-earnings-growth ratio of 2.45 and a beta of 0.55. The company’s 50 day simple moving average is $85.81 and its 200 day simple moving average is $85.48.
Medtronic Company Profile
Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.
Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).
Featured Stories
- Five stocks we like better than Medtronic
- Salesforce Looks Overbought, But the Rally May Be Far From Over
- Radar Anomaly: Draganfly’s Options Surge Signals Strategy Shift
- Boarding Call: EHang Secures First-Mover Altitude
- 3 Space Stocks: Ready for Liftoff or Burning Up on Reentry?
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
